Nasdaq

PMV Pharma Announces Closing of $243.5 Million Initial Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

CRANBURY, N.J., Sept. 29, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc., a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies ...
Nasdaq

PMV Pharma Appoints p53 Pioneer Dr. Guillermina Lozano to Scientific Advisory Board

CRANBURY, N.J., Feb. 16, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic ...
Business Wire

PMV Pharma Announces $30 Million Raised in Series A Financing

DOYLESTOWN, Pa.--(BUSINESS WIRE)--PMV Pharmaceuticals, Inc., a leader in the discovery and development of p53 targeted small molecule drugs for the treatment of cancer, announced today the completion ...
Yahoo Finance

PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

PRINCETON, N.J., Oct. 24, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. ("PMV Pharma" or the "Company"; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of ...
Yahoo Finance

PMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate Highlights

PRINCETON, N.J., Nov. 12, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of ...
Business Wire

PMV Pharma and Chiromics Announce Licensing Agreement and Drug Discovery Collaboration

DOYLESTOWN, Pa. & PRINCETON, N.J.--(BUSINESS WIRE)--PMV Pharmaceuticals, Inc., and Chiromics LLC today announced that they have entered into a collaboration whereby PMV Pharma has a non-exclusive ...
Business Insider

PMV Pharma Granted FDA Fast Track Designation of PC14586 for the Treatment of Advanced Cancer Patients that have Tumors with a p53 Y220C Mutation

CRANBURY, N.J., Oct. 13, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc., (Nasdaq: PMVP) a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic ...
Yahoo Finance

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences

A live audio webcast of the events will be available online at Events & Presentations. An archived replay of PMV Pharma's presentations will be available for 90 days following the webcast at Events & ...
WPRI 12

Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator

BOSTON and PRINCETON, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ: PMVP; “PMV Pharma”) today announced a partnership to develop Foundation ...
FierceBiotech

PMV Pharma Announces $30 Million Raised in Series A Financing

DOYLESTOWN, Pa.--PMV Pharmaceuticals, Inc., a leader in the discovery and development of p53 targeted small molecule drugs for the treatment of cancer, announced today the completion of a $30 million ...